Simone Song

Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.

Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.

Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.

TriSalus Operating Life Sciences, Inc. develops infusion systems for the interventional radiology and oncology markets. Its infusion systems are designed to deliver embolic agents through a micro-catheter with an expandable tip that collapses in forward flow and expands the vessel wall in reverse flow to increase targeted delivery, minimize reflux, and reduce damage to healthy tissue. The company was founded by Aravind Arepally and James E. Chomas in 2011 and is headquartered in Westminster, CO.

Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom.

Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom.